search
Home  /  Products  /  Radiotherapy  /  AccuKnife  /  Clinical Data  /  
FDA clears Direx Accusoft for Intensity Modulated Radiation Therapy (IMRT)


Direx Systems Corporation announced that it has received FDA clearance for an expanded application of the AccuSoft to include Intensity Modulated Radiation Therapy (IMRT). AccuSoft is the treatment planning system of AccuKnife, a family of advanced products for the radiation treatment of cancer.

AccuKnife upgrades medical linear accelerators, currently operating in hospitals and cancer clinics, to stereotactic radiosurgery (SRS), conformal 3D radiation therapy, and intensity modulated radiation therapy (IMRT). In addition to AccuSoft, AccuKnife includes AccuLeaf, a unique 4-bank multi-leaf collimation system, providing the highest resolution field definition in clinical radiation therapy.

AccuSoft is a PC-based system featuring image-based planning with proprietary convolution calculation algorithms resulting in fast dose calculation together with accurate representation of the radiation dose distribution. AccuSoft includes both forward and inverse treatment planning, full 3D imaging and dose display, stream-lined commissioning protocol, and DICOM network compatibility. In addition, the AccuLeaf supports the unique 4-bank collimator geometry of the AccuLeaf multi-leaf collimator.

Direx will exhibit the AccuSoft treatment planning system and other radiotherapy products at the AAPM 2004 meeting in Pittsburgh, PA (booth number 132), the ASTRO 2004 meeting in Atlanta, GA and the ESTRO 2004 meeting in Amsterdam and JASTRO 2004 in Chiba, Japan.





Additional News:
Intensity Modulated Radiotherapy on Treatment of Brain Tumors-Dynamic Arc Technique with Micromultileaf (IMAT)
Radiosurgery Associated with Intensity Modulated Radiotherapy on Cerebral Metastasis- Dynamic Arc Technique with Micromultileaf (Imat)
Comparison Between Intensity, Modulated Radiotherapy With Dynamic Arc Technique (IMAT) and Conventional Three Dimensional Radiotherapy (3DCRT) on Treatment of Prostate Cancer